CUTANEOUS MELANOMA. CURRENT DIAGNOSTIC AND THERAPEUTIC GUIDELINES WITH COMPARISON OF POLISH AND INTERNATIONAL CLINICAL PRACTICE AND FUTURE PERSPECTIVES

Wiktoria Łuniewska; Maurycy Jabłoński; Laura  Kobaka; Jakub  Chołast; Jakub  Kacer; Julia  Kacer; Jakub  Niepokój; Klaudia  Jurga; Marta  Modrzyk

doi:10.31435/ijitss.2(50).2026.5917

Authors

Wiktoria Łuniewska Medical University of Wroclaw, Wrocław, Poland https://orcid.org/0009-0009-5398-422X
Maurycy Jabłoński Poznan University of Medical Sciences, Poznan, Poland https://orcid.org/0009-0006-6793-6534
Laura Kobaka Poznan University of Medical Sciences, Poznan, Poland https://orcid.org/0009-0007-1010-3467
Jakub Chołast Lower Silesian Oncology Center, Wroclaw, Poland https://orcid.org/0009-0006-7180-2029
Jakub Kacer Lower Silesian Oncology Center, Wroclaw, Poland https://orcid.org/0009-0005-8573-0815
Julia Kacer Medical University of Wroclaw, Wrocław, Poland https://orcid.org/0009-0005-1709-3236
Jakub Niepokój Medical University of Wroclaw, Wrocław, Poland https://orcid.org/0009-0003-5273-4532
Klaudia Jurga Poznan University of Medical Sciences, Poznan, Poland https://orcid.org/0009-0004-3676-8166
Marta Modrzyk Institute of Medical Sciences, Opole, Poland https://orcid.org/0009-0003-9590-5602

DOI:

https://doi.org/10.31435/ijitss.2(50).2026.5917

Keywords:

Melanoma, ESMO Guidelines, Adjuvant Therapy, Immunotherapy, Targeted Therapy, Sentinel Lymph Node Biopsy, Poland

Abstract

Research objectives: Cutaneous melanoma is one of the most aggressive skin malignancies, characterized by a high potential for metastasis and a steadily increasing global incidence. While early-stage disease is associated with high cure rates, advanced melanoma has historically carried a poor prognosis, which has driven rapid advancements in both diagnostic technologies and systemic therapeutic strategies over the last decade.

Aim: This narrative review aims to synthesize current international diagnostic and therapeutic guidelines (ESMO, NCCN, ASCO) and compare them with Polish clinical practice (PTOK), focusing on recent shifts in surgical management, the role of adjuvant therapies, and future perspectives in personalized medicine and artificial intelligence.

Material and methods: The study is a narrative review based on the analysis of 21 recent peer-reviewed sources, including randomized controlled trials (RCTs), large-scale multicenter real-world studies from Poland, and the latest 2024 Clinical Practice Guidelines from the European Society for Medical Oncology and the National Comprehensive Cancer Network

Key findings: International standards now emphasize a significant de-escalation of radical surgery, specifically recommending the omission of completion lymph node dissection (CLND) following a positive sentinel lymph node biopsy (SLNB) in favor of active ultrasound surveillance. Adjuvant systemic therapies including anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitors have become the standard of care for high-risk patients, significantly improving relapse-free survival. Real-world data from Poland demonstrate a rapid alignment with these global trends, although challenges persist, as Polish patients are often diagnosed at more advanced stages, with a mean Breslow thickness of approximately 2.0 mm compared to <1.0 mm in Europe. Additionally, emerging deep learning architectures are showing outstanding potential, with diagnostic accuracies for melanoma detection exceeding 95%.

Conclusions: Successful melanoma management requires a multidisciplinary approach and strict adherence to evidence-based international guidelines. The transition to early systemic adjuvant therapy allows for the safe de-escalation of surgical interventions without worsening patient prognosis. Future management will increasingly rely on personalized medicine through molecular biomarkers, mRNA neoantigen vaccines, and the clinical integration of artificial intelligence to improve early detection and treatment planning.

References

Aldenhoven, L., Frotscher, C., Körver-Steeman, R., Martens, M. H., Kuburic, D., Janssen, A., et al. (2022). Sentinel lymph node mapping with superparamagnetic iron oxide for melanoma: A pilot study in healthy participants to establish an optimal MRI workflow protocol. BMC Cancer, 22. https://doi.org/10.1186/s12885-022-10146-w

Amaral, T., Ottaviano, M., Arance, A., Blank, C., Chiarion-Sileni, V., Donia, M., et al. (2025). Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of Oncology, 36, 10–30. https://doi.org/10.1016/j.annonc.2024.11.006

Caraviello, C., Nazzaro, G., Tavoletti, G., Boggio, F., Denaro, N., Murgia, G., et al. (2025a). Melanoma skin cancer: A comprehensive review of current knowledge. Cancers, 17. https://doi.org/10.3390/cancers17172920

Cybulska-Stopa, B., Czarnecka, A. M., Ostaszewski, K., Piejko, K., Zietek, M., Dziura, R., et al. (2022). e21539 Publication only: Sequential treatment with targeted and immune checkpoint inhibitor therapies in patients with BRAF positive metastatic melanoma: Real-world data. https://doi.org/10.1007/s11523-023-00954-w

Czarnecka, A. M., Błoński, P., Cybulska-Stopa, B., Bal, W., Dziura, R., Ciążyńska, M., et al. (2025). Encorafenib with binimetinib efficacy in the first, second, and third line of treatment for patients with advanced melanoma harboring a BRAF mutation—Real-world study. Oncology in Clinical Practice. https://doi.org/10.5603/ocp.107991

Frich, L., Hermann, R., Berentzen, Å., & Ryder, T. (2021). Randomized study of wound drainage on early complications after lymph node dissection for melanoma. Journal of Surgical Research, 267, 467–476. https://doi.org/10.1016/j.jss.2021.05.005

Jarell, A., Gadzia, J., Ackerman, L., Beard, T., Martin, B., Gimbel, M., et al. (2026). The 31-GEP provides personalized prognostic information beyond AJCC staging in patients with cutaneous melanoma. EJC Skin Cancer, 4, 100925. https://doi.org/10.1016/j.ejcskn.2026.100925

Kirkwood, J. M., Del Vecchio, M., Weber, J., Hoeller, C., Grob, J. J., Mohr, P., et al. (2023). Adjuvant nivolumab in resected stage IIB/C melanoma: Primary results from the randomized, phase 3 CheckMate 76K trial. Nature Medicine, 29, 2835–2843. https://doi.org/10.1038/s41591-023-02583-2

Kuchnicka, J., Kuchnicka, A., Kosz, K., Remjasz, K., Zarankiewicz, N., Zielińska, M., et al. (2022). Braf protein mutation and its significancy within patients with melanoma. Journal of Education, Health and Sport, 12, 938–944. https://doi.org/10.12775/JEHS.2022.12.08.076

Larkin, J., Weber, J., Del Vecchio, M., Gogas, H., Arance, A. M., Dalle, S., et al. (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. European Journal of Cancer, 173, 285–296. https://doi.org/10.1016/j.ejca.2022.06.041

Lazar, A. M., Costea, D. O., Popp, C. G., & Mastalier, B. (2024). Skin malignant melanoma and matrix metalloproteinases: Promising links to efficient therapies. International Journal of Molecular Sciences, 25. https://doi.org/10.3390/ijms25147804

Lipson, E. J., Hodi, F. S., Tawbi, H., Schadendorf, D., Ascierto, P. A., Matamala, L., et al. (2025). Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. European Journal of Cancer, 225. https://doi.org/10.1016/j.ejca.2025.115547

Long, G. V., Carlino, M. S., McNeil, C., Ribas, A., Gaudy-Marqueste, C., Schachter, J., et al. (2024). Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Annals of Oncology, 35, 1191–1199. https://doi.org/10.1016/j.annonc.2024.08.2330

Márquez-Rodas, I., Muñoz Couselo, E., Rodríguez Moreno, J. F., Arance Fernández, A. M., Berciano Guerrero, M. Á., Campos Balea, B., et al. (2024). SEOM-GEM clinical guidelines for cutaneous melanoma (2023). Clinical and Translational Oncology, 26, 2841–2855. https://doi.org/10.1007/s12094-024-03497-2

Matkowski, R., Simiczyjew, A., Ziętek, M., & Nowak, D. (2025). Stromal cells as a part of tumor microenvironment of melanoma: Their role in cancer progression and drug resistance. Advances in Clinical and Experimental Medicine, 34, 2005–2009. https://doi.org/10.17219/acem/211897

Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D. Y., Banerjee, S., González-Martín, A., et al. (2024). Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. Journal of Clinical Oncology, 42, 47–58. https://doi.org/10.1200/JCO.23.02005

Naseri, H., & Safaei, A. A. (2025a). Diagnosis and prognosis of melanoma from dermoscopy images using machine learning and deep learning: A systematic literature review. BMC Cancer, 25. https://doi.org/10.1186/s12885-024-13423-y

Naseri, H., & Safaei, A. A. (2025b). Diagnosis and prognosis of melanoma from dermoscopy images using machine learning and deep learning: A systematic literature review. BMC Cancer, 25. https://doi.org/10.1186/s12885-024-13423-y

Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., et al. (2021). Overall survival benefit with tebentafusp in metastatic uveal melanoma. New England Journal of Medicine, 385, 1196–1206. https://doi.org/10.1056/nejmoa2103485

Niemczyk, A., Miłek, M., Ślusarczyk, M., Stawska, W., Foryś, A., Kwaśniak, K., et al. (2024). Subungual melanoma—What you need to know about it: A literature review. Journal of Education, Health and Sport, 73, 51811. https://doi.org/10.12775/JEHS.2024.73.51811

Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., et al. (2023). Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma. New England Journal of Medicine, 388, 813–823. https://doi.org/10.1056/nejmoa2211437

Placzke, J., Rosińska, M., Sobczuk, P., Ziętek, M., Kempa-Kamińska, N., Cybulska-Stopa, B., et al. (2023). Modern approach to melanoma adjuvant treatment with anti-PD1 immune check point inhibitors or BRAF/MEK targeted therapy: Multicenter real-world report. Cancers, 15. https://doi.org/10.3390/cancers15174384

Rogala, P., Czarnecka, A. M., Cybulska-Stopa, B., Ostaszewski, K., Piejko, K., Ziętek, M., et al. (2022). Long term results and prognostic biomarkers for anti-PD1 immunotherapy used after BRAFi/MEKi combination in advanced cutaneous melanoma patients. Cancers, 14. https://doi.org/10.3390/cancers14092123

Rutkowski, P., Wysocki, P. J., Kozak, K., Nasierowska-Guttmejer, A., Jeziorski, A., Wysocki, W. M., et al. (n.d.). Wytyczne postępowania diagnostyczno-terapeutycznego: Postępowanie diagnostyczno-terapeutyczne u chorych na czerniaki—Zalecenia ekspertów. Expert recommendations on diagnostic-therapeutic management of melanoma patients. https://doi.org/10.5603/2021.0042

Schadendorf, D., Dummer, R., Flaherty, K. T., Robert, C., Arance, A., de Groot, J. W. B., et al. (2024). COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. European Journal of Cancer, 204. https://doi.org/10.1016/j.ejca.2024.114073

Seth, R., Agarwala, S. S., Messersmith, H., Alluri, K. C., Ascierto, P. A., Atkins, M. B., et al. (2023). Systemic therapy for melanoma: ASCO guideline update. Journal of Clinical Oncology, 41, 4794–4820. https://doi.org/10.1200/JCO.23.01136

Sorino, C., Iezzi, S., Ciuffreda, L., & Falcone, I. (2024). Immunotherapy in melanoma: Advances, pitfalls, and future perspectives. Frontiers in Molecular Biosciences, 11. https://doi.org/10.3389/fmolb.2024.1403021

Surov, A., Meyer, H. J., & Wienke, A. (2022). Role of sarcopenia in advanced malignant cutaneous melanoma treated with immunotherapy: A meta-analysis. Oncology, 100, 498–504. https://doi.org/10.1159/000525928

Swetter, S. M., Johnson, D., Albertini, M. R., Barker, C. A., Bateni, S., Baumgartner, J., et al. (2024). Melanoma: Cutaneous, version 2.2024 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 22, 290–298. https://doi.org/10.6004/jnccn.2024.0036

Szlasa, W., Sauer, N., Baczyńska, D., Ziętek, M., Haczkiewicz-Leśniak, K., Karpiński, P., et al. (2024). Pulsed electric field induces exocytosis and overexpression of MAGE antigens in melanoma. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-63181-x

Szostak, A. P., Szopińska, K., Graca, M., Śmigielska-Mikołajczyk, M. J., Łowicka, W., Dyląg, L., et al. (2024). Prevention and early detection of the most aggressive skin cancer: Melanoma. Quality in Sport, 22, 54608. https://doi.org/10.12775/QS.2024.22.54608

Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., et al. (2022). Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. New England Journal of Medicine, 386, 24–34. https://doi.org/10.1056/nejmoa2109970

Weber, J. S., Schadendorf, D., Del Vecchio, M., Larkin, J., Atkinson, V., Schenker, M., et al. (2022). Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). Journal of Clinical Oncology, 41, 517–527. https://doi.org/10.1200/JCO.22

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Christopher, et al. (2021). Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. Journal of Clinical Oncology, 40, 127–137. https://doi.org/10.1200/JCO.21

Wolchok, J. D., Chiarion-Sileni, V., Rutkowski, P., Cowey, C. L., Schadendorf, D., Wagstaff, J., et al. (2025). Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine, 392, 11–22. https://doi.org/10.1056/nejmoa2407417

Wong, M. K., Milhem, M. M., Sacco, J. J., Michels, J., In, G. K., Couselo, E. M., et al. (2025). RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (IGNYTE). Journal of Clinical Oncology. https://doi.org/10.1200/JCO-25-01346

Wysocki, W. M., Kulbat, A., Krzysztofik, M., Richter, K., Wójtowicz, E., Wysocka, J. B., et al. (2024). Post-treatment surveillance principles for selected skin cancers—Recommendations of the Surveillance Standardization Section of the Polish Oncology Society. Nowotwory, 74, 197–202. https://doi.org/10.5603/njo.99894

Al Zegair, F., Naranpanawa, N., Betz-Stablein, B., Janda, M., Soyer, H. P., & Chandra, S. S. (n.d.). Application of machine learning in melanoma detection and the identification of “ugly duckling” and suspicious naevi: A review. https://doi.org/10.48550/arXiv.2309.00265

Ziętek, M., Nowacki, M., Wierzbicki, J., Nowacka, K., Madej, I., Pawlak, E., et al. (2025). Assessing melanoma patients’ satisfaction with treatment and clinical care: Preliminary findings from a novel regional pilot program. Advances in Dermatology and Allergology, 42, 599–605. https://doi.org/10.5114/ada.2025.158233

Ziętek, M., Teterycz, P., Wierzbicki, J., Jankowski, M., Las-Jankowska, M., Zegarski, W., et al. (2023). The current treatment trends and survival patterns in melanoma patients with positive sentinel lymph node biopsy (SLNB): A multicenter nationwide study. Cancers, 15. https://doi.org/10.3390/cancers15102667

Ziętek, M., Wierzbicki, J., Pawlak, E., Maciejczyk, A., & Matkowski, R. (2022). Introduction of a pilot program to measure and improve the clinical care of melanoma patients in the Lower Silesian Voivodeship in Poland: A report of 20 months experience. BMC Cancer, 22. https://doi.org/10.1186/s12885-022-10253-8